Newsbenzinga
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
· Published
Article summary
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.
An excerpt from the original article.
Comments —
Loading comments…